Gemcitabine DNA Synthesis Inhibitor, 50mg and 1 more item

The University of Virginia awarded a purchase order (A207_PO-0446730) to Selleck Chem LLC on June 9, 2026, for the procurement of specialized pharmaceutical research compounds. The contract, valued at $384, encompasses two line items: Gemcitabine DNA Synthesis Inhibitor (50 milligrams) at $147 per unit and MRTX1133 KRAS-G12D inhibitor (10 millimolar concentration) at $237 per unit. Both items are being delivered to Selin Ustel and represent single-unit purchases.

This purchase order reflects the University of Virginia's acquisition of research-grade chemical compounds for use in its institutional research activities within the Commonwealth of Virginia. The modest contract value and single-unit quantities indicate this is a specialized, targeted procurement to support ongoing research operations rather than a broad-based supply agreement. The pharmaceutical compounds specified suggest applications in cancer research and molecular biology studies conducted by the university's research programs.